7
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9459 |
GR103545
|
Others | Others |
GR103545 是 κ-阿片受体的选择性激动剂,它是一种放射性示踪剂,可以用作体内成像。 | |||
T77374 |
Ontuxizumab
MORAb-004 |
Others | Others |
Ontuxizumab (MORAb-004) 是一种靶向内髓酸的单克隆抗体,具有抗肿瘤作用。Ontuxizumab 是一种有效的 IgG1/κ 抗内皮素 (TEM-1 或 CD248) 的单克隆抗体,可用于治疗转移性黑色素瘤。 | |||
T69475 |
Dinalbuphine sebacate
|
||
Dinalbuphine sebacate is a long-lasting prodrug of nalbuphine, acting as a moderate-efficacy partial agonist or antagonist of the μ-opioid receptor and as a high-efficacy partial agonist of the κ-opioid receptor. | |||
T81297 |
Renvistobart
|
||
Renvistobart为针对[Homo sapiens(含Ig结构域及ITIM、VSIG9、VSTM3的T细胞免疫受体)]的Homo sapiens IgG1-κ型单克隆抗体。 | |||
T40510 |
Ac-RYYRWK-NH2 TFA
Ac-RYYRWK-NH2 TFA |
||
Ac-RYYRWK-NH2 is a highly effective and specific partial agonist for the nociceptin receptor (NOP). It demonstrates a remarkable affinity for rat cortical membranes ORL1, with [3H]Ac-RYYRWK-NH2 exhibiting a Kd value of 0.071 nM. However, it shows negligible affinity towards μ-, κ-, or δ-opioid receptors. | |||
T71491 | Enadoline (Free Base) | ||
Enadoline (Free Base) is a kappa-opioid receptor agonist; PD 129290 (CAM 570; CI 977) is the S,S(-)-enantiomer; PD 129289 (CAM 569) is the corresponding R,R(+)-enantiomer. In human studies, it produced visual distortions and feelings of dissociation, reminiscent of the effects of salvinorin A. It was studied as a potential analgesic, but abandoned because of the dose-limiting effects of dysphoria, which could be expected from a κ-opioid agonist. There was mention of its potential in treating com... | |||
T72696 |
UCK2 Inhibitor-3
|
||
UCK2 Inhibitor-3是一款UCK2 (尿苷胞苷激酶2)的非竞争性抑制剂,其IC50值为16.6 μM。该化合物能在一定程度上补偿因感染或快速分裂的细胞中DHODH (二氢旋酸脱氢酶)功能的缺失,有效地挽救尿苷。此外,UCK2 Inhibitor-3还能抑制DNA聚合酶η和κ,其IC50值分别为56 μM和16 μM。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T83913 |
Mitraciliatine
|
||
Mitraciliatine是一种在M. speciosa(泰国称为Kratom)中发现的生物碱,是μ-阿片受体(MOR)部分激动剂和κ-阿片受体(KOR)激动剂。该化合物对MOR和KOR具有选择性,与δ-阿片受体(DOR; EC50s分别为228, 218, 和 >1,000 nM,针对小鼠受体在GTPγS结合实验中的表现)。Mitraciliatine(100 nmol/动物,脑室内注射)在小鼠的热水尾部缩回实验中延长了撤回潜伏期,这一效果可以通过敲除MOR而非KOR来逆转。与吗啡不同,Mitraciliatine不会诱发过度活动或呼吸抑制。 |